To test whether the suppression of HIF-1α can be explored as a treatment strategy for PEL, we utilized PX-478, a small molecule that has been shown to potently inhibit the expression of HIF-1α [52] in a variety of tumor models [53] and mice [54]. The gene discussed is HIF1A; the disease is primary effusion lymphoma.